4
Changes in Ownership
Aligos Therapeutics, Inc. Filed Acc 0001610717-24-000097
Options or other derivatives
- See Remarks acquired 152,570 shares (grant or award)
- See Remarks returned 331,250 shares (to the company)
From the SEC's structured data for this filing
Trades in this filing
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Symons Julian A. See Remarks | 2024-02-27 | Returned to the company · Stock Option (Right to Buy) | −200,000 | 0 | D: show line 1 in the form | |||||
| Symons Julian A. See Remarks | 2024-02-27 | Returned to the company · Stock Option (Right to Buy) | −105,000 | 0 | D: show line 2 in the form | |||||
| Symons Julian A. See Remarks | 2024-02-27 | Returned to the company · Stock Option (Right to Buy) | −26,250 | 0 | D: show line 3 in the form | |||||
| Symons Julian A. See Remarks | 2024-02-28 | Grant or award · Stock Option (Right to Buy) | +58,822 | 58,822 | D: show line 4 in the form | |||||
| Symons Julian A. See Remarks | 2024-02-28 | Grant or award · Stock Option (Right to Buy) | +74,998 | 74,998 | D: show line 5 in the form | |||||
| Symons Julian A. See Remarks | 2024-02-28 | Grant or award · Stock Option (Right to Buy) | +18,750 | 18,750 | D: show line 6 in the form |
Loading xslF345X05/form4.xml…